Brugada syndrome drugs to avoid

Brugada syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Brugada syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Examples of Type I Brugada Syndrome
Chest X Ray
Echocardiography or Ultrasound
Electrophysiologic Studies
Genetic Testing
Treatment
Treatment
Drugs to Avoid
Drugs to Preferably Avoid
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Brugada syndrome drugs to avoid On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Brugada syndrome drugs to avoid All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Brugada syndrome drugs to avoid
CDC on Brugada syndrome drugs to avoid
Brugada syndrome drugs to avoid in the news
Blogs on Brugada syndrome drugs to avoid
Directions to Hospitals Treating Brugada syndrome
Risk calculators and risk factors for Brugada syndrome drugs to avoid

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

There are certain drugs that should be avoided in patients with Brugada syndrome. These drugs include ajmaline, flecainide, pilsicainide, procainamide, and propafenone. These drugs are all sodium blocking antiarrhythmics which are either in the IA class or IC class.

Drugs to Avoid

The following drugs should be avoided in patients with Brugada syndrome.

Generic name	Brand name®	Class / Clinical use	References	Recommendation
Ajmaline	e.g. Gilurytmal® - more brand names here -	Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias	Brugada 1997 Rolf 2003 Wolpert 2005 Bébarová 2005	Class I
Flecainide	e.g. Tambocor® - more brand names here -	Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias	Krishnan 1998 Brugada 2000 Gasparini 2003 Meregalli 2006 Stokoe 2007	Class I
Pilsicainide	e.g. Sunrhythm® - more brand names here -	Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias	Takenaka 1999 Fujiki 1999 Takagi 2002 Kimura 2004	Class I
Procainamide	e.g. Procan® Pronestyl® - more brand names here -	Antiarrhythmic Agent (1A: Na-blocker) / Arrhythmias	Miyazaki 1996 Brugada 1997 Joshi 2007 Villemaire 1992	Class I
Propafenone	e.g. Rythmol® - more brand names here -	Antiarrhythmic Agent (1C: Na-blocker) / Arrhythmias	Matana 2000 Akdemir 2002 Hasdemir 2006 Shan 2008 Stark 1996	Class IIa

Recommendation: Class I: convincing evidence/opinion; Class IIa: evidence/opinion less clear; Class IIb: conflicting evidence/opinion; Class III: very little evidence.